etidronate has been researched along with Pseudoxanthoma Elasticum in 11 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Pseudoxanthoma Elasticum: An inherited disorder of connective tissue with extensive degeneration and calcification of ELASTIC TISSUE primarily in the skin, eye, and vasculature. At least two forms exist, autosomal recessive and autosomal dominant. This disorder is caused by mutations of one of the ATP-BINDING CASSETTE TRANSPORTERS. Patients are predisposed to MYOCARDIAL INFARCTION and GASTROINTESTINAL HEMORRHAGE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect of the bisphosphonate etidronate on choroidal neovascular (CNV) activity in patients with pseudoxanthoma elasticum (PXE)." | 9.34 | The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum. ( de Jong, PA; Imhof, SM; Mali, WPTM; Ossewaarde-van Norel, J; Risseeuw, S; Spiering, W; van Leeuwen, R, 2020) |
| "In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks)." | 9.27 | Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. ( Bartstra, JW; de Jong, PA; de Vries, JJ; den Harder, AM; Imhof, SM; Kranenburg, G; Lagerweij, SJ; Lam, MG; Luurtsema, G; Mali, WP; Ossewaarde-van Norel, J; Risseeuw, S; Slart, RHJA; Spiering, W; van Leeuwen, R; Verhaar, HJ; Visseren, FLJ, 2018) |
| "Etidronate treatment halts systemic arterial calcification in PXE." | 6.94 | Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum. ( Bartstra, JW; de Jong, PA; den Harder, AM; Isgum, I; Kranenburg, G; Mali, WPTM; Spiering, W; Wijsman, A; Wolf, B; Wolterink, JM, 2020) |
| "To assess the effect of the bisphosphonate etidronate on choroidal neovascular (CNV) activity in patients with pseudoxanthoma elasticum (PXE)." | 5.34 | The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum. ( de Jong, PA; Imhof, SM; Mali, WPTM; Ossewaarde-van Norel, J; Risseeuw, S; Spiering, W; van Leeuwen, R, 2020) |
| "In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks)." | 5.27 | Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. ( Bartstra, JW; de Jong, PA; de Vries, JJ; den Harder, AM; Imhof, SM; Kranenburg, G; Lagerweij, SJ; Lam, MG; Luurtsema, G; Mali, WP; Ossewaarde-van Norel, J; Risseeuw, S; Slart, RHJA; Spiering, W; van Leeuwen, R; Verhaar, HJ; Visseren, FLJ, 2018) |
| "Etidronate treatment halts systemic arterial calcification in PXE." | 2.94 | Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum. ( Bartstra, JW; de Jong, PA; den Harder, AM; Isgum, I; Kranenburg, G; Mali, WPTM; Spiering, W; Wijsman, A; Wolf, B; Wolterink, JM, 2020) |
| "Pseudoxanthoma elasticum is a prototype of heritable ectopic mineralization disorders, with phenotypic overlap with generalized arterial calcification of infancy and arterial calcification due to CD73 deficiency." | 2.55 | Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016. ( Li, Q; Terry, SF; Uitto, J; van de Wetering, K; Váradi, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Kauffenstein, G | 1 |
| Chappard, D | 1 |
| Leftheriotis, G | 1 |
| Martin, L | 2 |
| Bartstra, JW | 2 |
| de Jong, PA | 3 |
| Kranenburg, G | 2 |
| Wolterink, JM | 1 |
| Isgum, I | 1 |
| Wijsman, A | 1 |
| Wolf, B | 1 |
| den Harder, AM | 2 |
| Mali, WPTM | 2 |
| Spiering, W | 3 |
| Risseeuw, S | 2 |
| van Leeuwen, R | 2 |
| Imhof, SM | 2 |
| Ossewaarde-van Norel, J | 2 |
| Stumpf, MJ | 1 |
| Schaefer, CA | 1 |
| Schahab, N | 1 |
| Uitto, J | 3 |
| Li, Q | 3 |
| van de Wetering, K | 2 |
| Váradi, A | 2 |
| Terry, SF | 2 |
| Pomozi, V | 1 |
| Brampton, C | 1 |
| Zoll, J | 1 |
| Calio, B | 1 |
| Pham, K | 1 |
| Owens, JB | 1 |
| Marh, J | 1 |
| Moisyadi, S | 1 |
| Bauer, C | 1 |
| Erdmann, J | 1 |
| Aherrahrou, Z | 1 |
| Le Saux, O | 1 |
| Lagerweij, SJ | 1 |
| Lam, MG | 1 |
| Verhaar, HJ | 1 |
| de Vries, JJ | 1 |
| Slart, RHJA | 1 |
| Luurtsema, G | 1 |
| Visseren, FLJ | 1 |
| Mali, WP | 1 |
| Apschner, A | 1 |
| Huitema, LF | 1 |
| Ponsioen, B | 1 |
| Peterson-Maduro, J | 1 |
| Schulte-Merker, S | 1 |
| Sundberg, JP | 1 |
| Levine, MA | 1 |
| Moore, SN | 1 |
| Tanner, SB | 1 |
| Schoenecker, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)[NCT03813550] | 20 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)[NCT04660461] | Phase 4 | 20 participants (Anticipated) | Interventional | 2020-02-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for etidronate and Pseudoxanthoma Elasticum
| Article | Year |
|---|---|
Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016.
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Animals; Biopsy, Needle; Clinical Trials as Topic; Congresses | 2017 |
3 trials available for etidronate and Pseudoxanthoma Elasticum
| Article | Year |
|---|---|
Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum.
Topics: Aged; Arteries; Etidronic Acid; Female; Humans; Male; Middle Aged; Pseudoxanthoma Elasticum; Single- | 2020 |
The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum.
Topics: Aged; Choroidal Neovascularization; Double-Blind Method; Drug Administration Schedule; Etidronic Aci | 2020 |
Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Calcium; Drug Monitoring; Etidronic Acid; Fema | 2018 |
7 other studies available for etidronate and Pseudoxanthoma Elasticum
| Article | Year |
|---|---|
ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?
Topics: Bone Diseases, Metabolic; Etidronic Acid; Humans; Multidrug Resistance-Associated Proteins; Mutation | 2022 |
From osteoporosis to pseudoxanthoma elasticum - etidronate in a vascular disease.
Topics: Etidronic Acid; Humans; Osteoporosis; Pseudoxanthoma Elasticum; Vascular Calcification; Vascular Dis | 2020 |
Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice.
Topics: Acute Disease; Animals; ATP-Binding Cassette Transporters; Calcinosis; Chronic Disease; Diphosphates | 2017 |
Vascular Mineralization in Pseudoxanthoma Elasticum: Etidronate to the Rescue?
Topics: Etidronic Acid; Humans; Pseudoxanthoma Elasticum; Vascular Calcification | 2018 |
Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE).
Topics: Animals; Biomarkers; Calcinosis; Calcium; Choristoma; Etidronic Acid; Fibroblast Growth Factor-23; H | 2014 |
The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Drug Eval | 2015 |
Bisphosphonates: from softening water to treating PXE.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Etidronic | 2015 |